| Prime‑editing for Duchenne Muscular Dystrophy (DMD) |
A new CRISPR‑based prime‑editor delivered via an AAV vector corrects the most common DMD mutation in patient‑derived muscle cells |
It demonstrates a “one‑shot” gene correction that could spare patients from lifelong therapy |
First‑in‑human phase I/II trial launched in early September 2026; early safety data look promising. |
| AI‑generated small‑molecule inhibitors for KRAS G12C |
An AI platform (DeepDock‑X) designed novel inhibitors that bind the KRAS G12C pocket with higher potency than previous drugs |
KRAS G12C is a “druggable” mutant in lung cancer; these inhibitors hit it from a new chemical class |
Phase I data released: 30% objective response rate in heavily pre‑treated NSCLC patients. |
| mRNA‑based treatment for transthyretin amyloidosis |
An mRNA therapeutic that encodes a stabilizing antibody fragment to prevent amyloid fibril formation |
Avoids the need for lifelong plasma exchanges or liver transplantation |
Phase II trial showed ≥50 % reduction in TTR protein levels after 12 weeks. |
| 3‑D bioprinted liver organoids for drug toxicity testing |
A consortium of biotech firms produced fully perfused, bioprinted liver organoids that recapitulate human metabolism |
Reduces reliance on animal testing and improves prediction of hepatotoxicity |
Commercial platform now in early‑phase partnership with major pharma; FDA cleared for in‑silico toxicology. |
| Universal CAR‑T cell platform |
A “plug‑and‑play” CAR‑T product that can be quickly customized by swapping a single antibody domain |
Makes CAR‑T therapy adaptable for multiple cancers without manufacturing a new cell line each time |
First multicenter safety study (N = 120) reported in the Lancet Oncology—median 1‑year survival 88 % for relapsed B‑cell ALL. |
| Gene‑edited, hypoimmunogenic organoids for transplant |
Organoids derived from patient iPSCs engineered to lack HLA class I & II expression, reducing rejection risk |
Could eliminate the need for lifelong immunosuppression |
First successful pig‑to‑human organoid transplant model demonstrated in a non‑human primate study. |